Eluphor, 200 mg/5 ml suspension 90 ml

It is assumed that antimicrobial activity of nifuroxazide is caused by the presence of NO2-group in its composition, which causes inhibition of dehydrogenase activity and disrupts protein synthesis in pathogenic bacteria.
Active against Gram-positive microorganisms (Streptococcus aureus, Staphylococcus pyogenes, Clostridium), Gram-negative enterobacteriaceae (Escherihia coli, Salmonella spp, Shigella spp., Klebsiella spp., Enterobacter spp., Vibrio cholerae, Campylobacter jejuni, Edwarsiella, Citrobacter, Yersinia enterocolitica). In acute bacterial diarrhea it restores intestinal eubiosis. In case of infection with enterotropic viruses it prevents the development of bacterial superinfection.

Pharmacokinetics
After oral administration nifuroxazide is practically not absorbed from the digestive tract and its antibacterial effect is exclusively in the intestinal lumen. It is completely eliminated through the gastrointestinal tract. The elimination rate depends both on the dose of the drug and on the motility of the intestinal tract.

Indications

Diarrhea of bacterial genesis;
Chronic lesions of the gastrointestinal tract of bacterial etiology, accompanied by dyspeptic symptoms.

Active ingredient

Nifuroxazide

Composition

The suspension contains:
Active ingredient: nifuroxazid 200,0 mg
Excipients: sucrose 1000,0 mg, sodium hydroxide 2,0 mg, methyl parahydroxybenzoate 5,0 mg, ethanol 96% 0,05 ml, carbomer 10,5 mg, citric acid 0,75 mg, banana flavoring 10,00 mg, water to 5,0 ml.

How to take, the dosage

It is administered orally.

For dosing use a dosage spoon of 5 ml with graduation of 2.5 ml.
The suspension should be shaken well before use.
Children 1-6 months: 2.5 ml 2-3 times a day (at intervals of 8 to 12 hours).
Children from 7 months to 2 years of age: 2.5 ml 4 times a day (at 8-hour intervals).
Children from 3 to 7 years of age: 5 ml 3 times a day (at 8-hour intervals).
Children over 7 years of age and adults: 5 ml 3-4 times a day (at 6-8-hour intervals). Therapy with nifuroxazide should not last more than 7 days.

Special Instructions

In treatment of diarrhea simultaneously with therapy with nifuroxazide rehydration therapy (oral or intravenous) should be conducted in accordance with the patient’s condition and intensity of diarrhea.
Alcohol use during therapy with nifuroxazide is prohibited.
Before administration of suspension in infants should be excluded their congenital deficiency of sucrose digesting enzymes.

Influence on driving and operating machinery

The drug does not affect psychomotor performance and ability to drive and operate machinery.

Contraindications

Hypersensitivity to nitrofuran derivatives or other drug components;
Fructose intolerance;
Glucose-galactose malabsorption syndrome, insufficiency of sugar and isomaltase;
Neonatal period (less than 1 month), prematurity.

Side effects

Allergic reactions, nausea, vomiting.

Overdose

The drug is not absorbed from the gastrointestinal tract and does not enter the systemic circulation. Symptoms of overdose are not known. In case of overdose gastric lavage and symptomatic treatment are recommended.

Similarities

Enterofuryl, Nifuroxazid, Stopdiar, Ecofuryl, Adisord, Nifural, Elufor